A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells  by Hayakawa, Takao et al.
lable at ScienceDirect
Regenerative Therapy 2 (2015) 81e94Contents lists avaiRegenerative Therapy
journal homepage: http: / /www.elsevier .com/locate/rethOriginal articleA study on ensuring the quality and safety of pharmaceuticals and
medical devices derived from processing of autologous human
induced pluripotent stem(-like) cells*
Takao Hayakawa a, *, Takashi Aoi b, c, Akihiro Umezawa d, Keiya Ozawa e, Yoji Sato f,
Yoshiki Sawa g, Akifumi Matsuyama h, Shinya Yamanaka i, Masayuki Yamato j
a Pharmaceutical Research and Technology Institute, Kindai University, Japan
b Department of iPS Cell Applications, Graduate School of Medicine, Kobe University, Japan
c Center for Human Resource Development for Regenerative Medicine, Kobe University Hospital, Japan
d Department of Reproductive Biology, National Research Institute for Child Health and Development, Japan
e Division of Genetic Therapeutics, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan
f Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Japan
g Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, Japan
h R&D Division of Regenerative Medicine, Foundation for Biomedical Research and Innovation, Japan
i Center for iPS Cell Research and Application, Kyoto University, Japan
j Advanced Biomedical Science Center, Tokyo Women's Medical University, Japana r t i c l e i n f o
Article history:
Received 24 March 2015
Accepted 23 June 2015
Keywords:
Autologous hiPS(-like) cells
Quality and safety of pharmaceuticals and
medical devices
Regenerative medicine
Human stem cell-based products* Recently, this type of product has been deﬁned a
ceutical Affairs Law -renamed the Pharmaceuticals a
Governmental Regulatory System for Stem CelleBase
* Corresponding author.
E-mail addresses: takao-hayakawa@mtg.biglobe.ne
Peer review under responsibility of the Japanese
http://dx.doi.org/10.1016/j.reth.2015.06.002
2352-3204/© 2015, The Japanese Society for Regener
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
As a series of endeavors to establish suitable measures for the sound development of regenerative
medicine using human stem cell-based products, we studied scientiﬁc principles, concepts, and basic
technical elements to ensure the quality and safety of therapeutic products derived from autologous
human iPS cells or iPS cell-like cells, taking into consideration scientiﬁc and technological advances,
ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the
development of the Japanese ofﬁcial Notiﬁcation No. 0907-4, “Guideline on Ensuring the Quality and
Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human
Induced Pluripotent Stem(-Like) Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of
Health, Labour and Welfare of Japan, on September 7, 2012. The present paper addresses various aspects
of products derived from autologous human iPS cells (or iPS cell-like cells), in addition to similar points
to consider that are described previously for autologous human stem cell-based products. Major addi-
tional points include (1) possible existence of autologous human iPS cell-like cells that are different from
iPS cells in terms of speciﬁc biological features; (2) the use of autologous human iPS(-like) cells as
appropriate starting materials for regenerative medicine, where necessary and signiﬁcant; (3) estab-
lishment of autologous human iPS(-like) cell lines and their characterization; (4) cell banking and/or
possible establishment of intermediate cell lines derived from autologous human iPS(-like) cells at
appropriate stage(s) of a manufacturing process, if necessary; and (5) concerns about the presence of
undifferentiated cells in the ﬁnal product; such cells may cause ectopic tissue formation and/or
tumorigenesis. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as
possible to the patients with severe diseases that are difﬁcult to treat with conventional modalities.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).s a distinct product from both conventional pharmaceuticals and medical devices according to the revised Pharma-
nd Medical Devices, and Other Therapeutic Products Act. (Akinori Hara, Daisaku Sato, and Yasuyuki Sahara: New
d Therapies in Japan. Therapeutic Innovation & Regulatory Science. 2014; 48(6): 681e688).
.jp, hayakawatakao@gmail.com (T. Hayakawa).
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The details of the series of the present studies have been
described in the previous papers [1,2]. The present paper provides a
summary of points that are closely related to those in the ﬁrst
paper.
Development of regenerative medicine using cell-based prod-
ucts derived from the processing of human cells and tissues is
keenly anticipated in Japan because of difﬁculties in securing hu-
man organs and tissues in our country. With breakthroughs in
technology and advances in research, more and more people are
hopeful that this medical technology using novel cell-based prod-
ucts will result in the development of effective therapies.
In Japan, translational research on regenerative medicine is
advancing rapidly. In particular, much work has been done on
product development using human stem cells, i.e., somatic stem
cells such as mesenchymal stem cells, embryonic stem (ES) cells,
and induced pluripotent stem (iPS) cells. Thus, there is an urgent
need to prepare relevant guidelines on the evaluation of the
products expected to be developed in the near future. Identifying
the technical, medical, and ethical conditions necessary for utilizing
various types of stem cells at an early stage of development is vital
for their rapid application in clinical settings.
In the ﬁscal year 2008, the Japanese Ministry of Health, Labour
and Welfare decided to form a panel of experts: the “Study Group
on Ensuring the Quality and Safety of Pharmaceuticals and Medical
Devices Derived from Processing of Human Stem Cells.” The panel
was established as a scientiﬁc research project of the Ministry of
Health, Labour and Welfare and has subsequently been chaired by
Dr. Takao Hayakawa.
The objective of the study group is to promote the sound
development of products derived from human stem cells by
investigating scientiﬁc and technological advances, their ethical
validity, the regulatory rationale, and international trends in hu-
man stem cell-derived products, and to establish and implement
appropriate safety evaluation criteria.
As a result of the examination until 2009, in accordancewith the
Pharmaceutical Affairs Law, and with the goal of facilitating clinical
application of products derived from human somatic stem cells, iPS
cells, ES cells, and other cells, the study group concluded that to
facilitate the conduct of efﬁcient, effective, and rational research
and development (R&D), the relevant guidelines should be tailored
to speciﬁc cell sources and phenotypes (autologous human versus
allogeneic human, and somatic stem cells vs. iPS cells vs. ES cells vs.
other cells). Points to be considered include but are not limited to
relevant technical details, the manufacturing process, character-
ization, quality control, and stability evaluation as well as the data
required to determine the safety and efﬁcacy of the products.
In 2009, 2 interim reports on draft guidelines on autologous
human somatic stem cell-based products and autologous human
iPS(-like) cell-based products were developed based on the existing
Japanese Ministry of Health, Labour and Welfare Notiﬁcation No.
0208003 and on the above considerations. Three other interim
reports detailing draft guidelines were also developed for alloge-
neic human somatic stem cell-based products, allogeneic human
iPS(-like) cell-based products, and human ES cell-based products
according to Japanese Ministry of Health, Labour and Welfare
Notiﬁcation No. 0912006. These 5 sets of draft guidelines, still at the
interim stage, were presented as the subjects of thorough discus-
sions from a variety of viewpoints. They were widely circulated
among the interested parties as articles published in a relevant
scientiﬁc journal to elicit readers' comments (Hayakawa T., et al.:
Regenerative Medicine [Journal of the Japanese Society for Regen-
erative Medicine], 9, 116e180 [2010], in Japanese). Thereafter, these
articles were updated and published as a series of 8 articles (Journalof the Japanese Society for Regenerative Medicine, 10, 86e152
[2011]), which would form the basis of the ﬁnal draft guidelines.
After extensive discussions with the study group and after public
consultation, the Pharmaceutical and Food Safety Bureau of the
Ministry of Health, Labour and Welfare of Japan issued 5 notiﬁca-
tions on September 7, 2012, as described previously [1].
In this paper, in continuation of the previous papers [1,2], we
introduce guidelines on the basic technological requirements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of autologous human iPS(-like)
cells.
The generation of iPS cells by Yamanaka and colleagues
demonstrated that differentiated cells can be reprogrammed arti-
ﬁcially. This monumental work suggests that differentiation and
dedifferentiation can be manipulated as needed. The technology
raises great hopes of practical applications in basic biological
research, medical research on pathogenesis, drug discovery
through establishment of novel systems for efﬁcacy and toxicity
tests, and in regenerative medicine.
Needless to say, the ultimate goal of regenerative medicine is
to treat patients. Therefore, we should always adopt a treatment
(objective)-oriented approach and give priority to the consider-
ation of potential target diseases and products for development.
The paradigm shift brought by the discovery of iPS cells provides
limitless possibilities for regenerative medicine. This, however,
does not necessarily mean that all regenerative medicine should
be practiced on the presupposition of a standardized degree of
reprogramming or other properties of iPS cells. If iPS cells can be
standardized and their state of pluripotency made precisely
constant, iPS cells may serve as crucial and highly speciﬁc raw
materials for the development of cell-based pharmaceuticals and
medical devices for regenerative medicine. However, this does
not necessarily mean that all products shall be produced using a
speciﬁc iPS cell lineage. It is crucial to consider that when
manufacturing an individual product from a certain type of cells,
the cells chosen should be the “appropriate raw materials” for
the product. In other words, the most important criterion for
certain artiﬁcially induced pluripotent stem cells would be
whether they have been conﬁrmed to be a suitable raw material
for the manufacture of a ﬁnal product; this approach ensures
quality, efﬁcacy, and safety sufﬁcient for a speciﬁc treatment
(objective). The challenges for the researchers and developers
would include (1) which types of pluripotent stem cells to use as
a raw material: cell-of-origin, reprogramming method, and de-
gree of reprogramming; and (2) how to obtain the ﬁnal product
from the pluripotent stem cells: the differentiation protocol and
intermediate cell state.
Based on the concept mentioned above, these guidelines refer to
both “human iPS cells” and “human iPS-like cells” and provisionally
deﬁne these 2 types of cells as follows:
“Human induced pluripotent stem cells (iPS cells)”: Cells
generated from somatic cells through artiﬁcial reprogramming by
introducing genes or proteins, or, for instance, by chemical or drug
treatment, or cells that are obtained from such cells through cell
division, and which possess the ability to differentiate into the
endoderm, mesoderm, and ectoderm, and furthermore, maintain
the ability to self-renew or a similar ability.
“Human induced pluripotent stem-like cells (iPS-like cells)”:
Cells generated from somatic cells through artiﬁcial dedifferentia-
tion by introducing genes or proteins, or, for instance, by chemical
or drug treatment, or cells that are obtained from such cells through
cell division, and which at least possess the ability to differentiate
into some type of endoderm, mesoderm, or ectoderm, and
furthermore, to maintain the ability to self-renew or a similar
ability.
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or quality controlled due to their indistinct origin and complexity;
the same holds true for ﬁnal products due to their limited quantity
and complex quality attributes. To address these concerns, it is very
important to ensure constancy and robustness of the
manufacturing process in the production of all types of biologics.
The core technical element required is to establish base camp(s),
i.e., to prepare substrates for production of biologics at relevant
stage(s) in the manufacturing process; these substrates can be
extensively characterized and controlled and are of stable quality;
constant processing of these substrates into the subsequent in-
termediate(s) and ﬁnally to a desired product is achievable.
The ideal base camp(s) in the sustainablemanufacture of human
iPS or iPS-like cell-based products are cells (banks) and/or inter-
mediate cell products/lines that have been well characterized, are
stable per se but can propagate under appropriate conditions, can
be renewed, are ready for supply upon request, and can differen-
tiate into target cells. For certain ﬁnal products, it may be more
feasible for the consistent, safe manufacture of the desired products
to establish sustainable intermediate cell products/lines (as a form
of a cell bank) at an intermediate stage of the manufacturing pro-
cess, than to emphasize characterization, evaluation, or control of
cells at the raw-material stage, which may be difﬁcult to perform. It
is, of course, essential to explain the advantages and appropriate-
ness of such a procedure. When establishing cell lines at each stage
of differentiation with different phenotypes, procedures for the
process of cell generation such as differentiation, isolation, culti-
vation of target cells, generation of cell lines, the growth medium;
culture conditions; culture period; and survival rate should be
clearly documented and justiﬁed as much as possible. To maintain
consistency and stability of intermediate cell products/lines, critical
indicators such as purity, morphology, speciﬁc cell markers, kar-
yotypes, proliferation, and differentiation should be selected, and
acceptance criteria should be set accordingly. In addition, the pas-
sage number and/or population doublings of intermediate cell
products/lines should be speciﬁed so that quality meets the
acceptance criteria.
For products derived from human iPS cells or iPS-like cells
(hereafter referred to as iPS(-like) cells), the presence of undiffer-
entiated cells in ﬁnal products is a major safety concern (e.g.,
ectopic tissue formation and tumorigenesis). However, because this
concern is raised from one of iPS(-like) cells' strongest character-
istics, it is quite difﬁcult to avoid. Elimination of intrinsic charac-
teristics of iPS(-like) cells is a trade-off at least in principle, and is
thus considered very difﬁcult. Accordingly, it is necessary to have a
strategy and tactics to develop safer ﬁnal products by improving
manufacturing process and process control more effectively rather
than discussing safety issues at iPS(-like) cell level. These draft
guidelines, therefore, require demonstration of the absence of un-
differentiated cell contamination at the level of an iPS(-like) cell-
derived bank and/or intermediate and/or ﬁnal cell products by
thorough analysis, or an effort to develop efﬁcient methods to
eliminate or inactivate undifferentiated cells in the course of cell
processing. Furthermore, selection of administration methods will
help to minimize safety concerns. These guidelines also explain the
importance of technical development to generate and characterize
iPS(-like) cell-derived somatic stem cells, which may lead to safe,
stable, characteristically well-deﬁned, and appropriate raw mate-
rials. In addition, the need for R&D on examination techniques to
predict the pluripotency and the differentiation potential of each
iPS(-like) cell lineage and processing techniques to induce target
cells efﬁciently and properly and to isolate differentiated cells fromundifferentiated cells during processingwill provide novel business
opportunities.
These draft guidelines include discussion of all of the above-
stated aspects of iPS(-like) cells. The iPS(-like) cells possess
pluripotency and self-replication abilities exceeding those of
normal somatic stem cells and can therefore differentiate into a
variety of cell types, depending on the processing technique
used. Such iPS(-like) cell-based products may be clinically
applied heterologously, i.e., in an environment that differs from
the environment where the cells perform their natural endog-
enous function. Concerns about these points have been included
in these human iPS(-like) cell guidelines in reference to Japanese
Ministry of Health, Labour and Welfare Notiﬁcations No.
0208003 and No. 0912006, which serve as the basis for these
guidelines.
When interpreting and implementing the present guidelines,
the following arguments should be considered. The ultimate goal is
to provide novel therapies to patients by means of regenerative
medicine. The role of these guidelines is to present scientiﬁc
principles, concepts, ideas, and technical elements that should help
to achieve a speciﬁed goal in the most efﬁcient and effective
manner possible. Because a wide variety of products are antici-
pated, encompassing a variety of situations and circumstances,
these guidelines describe comprehensive points of concern. It is
necessary to determine the relevant testing parameters and eval-
uation methods by considering the characteristics of the cells in
question, the speciﬁc clinical objective, and the method of appli-
cation (among other parameters). Those items that are applicable
should be justiﬁed and put into practice in an appropriate and
ﬂexible manner.
Several points should be kept in mind with regard to the
development of products for regenerative medicine and the
implementation of this guideline. The desired products are ex-
pected to show promise as a novel therapeutic method as a result
of proof of concept (POC) and relevant data, indicating no critical
concerns about product safety that might impede to the use of
the products in humans for the ﬁrst time. Thorough observance
of the Declaration of Helsinki, including proper informed consent
and the right of self-determination of the patient, is
indispensable.
It should be emphasized again that our primary goal is to
offer suitable medical opportunities as soon as possible to pa-
tients with severe diseases that are difﬁcult to treat with con-
ventional modalities. The present guidelines should serve this
purpose. Therefore, it is important to interpret and employ these
guidelines ﬂexibly and meaningfully in this context. Stringent
observance of these guidelines without primary consideration of
the patient and his/her speciﬁc situation should be avoided.
Progress in the actual use of regenerative medicine is clearly
desirable for maintaining and improving human health. The devel-
opment of innovative and revolutionary medicinal products and
therapeutic techniques should be beneﬁcial to our countryaswell as
the international community and is a way to make a peaceful in-
ternational contribution that will be a legacy for all mankind. The
role of the government here is to promote clinical research and
industrialization; relevant regulations and guidelines are important
measures undertaken to achieve this common goal in a scientiﬁc,
rational, efﬁcient, and effective way. All those involved, like players
in the same arena with a common goal in mind, accumulating sci-
entiﬁc data and concentrating wisdom, should continue to make
efforts to deliver these revolutionary cell-based products and ther-
apeutic techniques to patients as soon as possible.
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cals andMedical Devices Derived from Processing of Autologous
Human Induced Pluripotent Stem(-Like) Cells. (Notiﬁcation No.
0907-4, issued by Pharmaceuticals and Food Safety Bureau, Min-
istry of Health, Labour andWelfare of Japan, on September 7, 2012).
2. Introduction
1. The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of autologous human
induced pluripotent stem (iPS) cells or autologous human iPS-
like cells. These products are hereafter referred to as autolo-
gous human iPS(-like) cell-based products or simply as the
“desired cell products.”
Autologous human iPS(-like) cell-based products are obtained
by artiﬁcially inducing differentiation of various types of iPS(-
like) cells generated artiﬁcially from autologous human so-
matic cells; they are used directly or after further processing.
There are many types of manufacturingmethods, intermediates,
types and characteristics of the desired cell products, and
methods for clinical application. In addition, the scientiﬁc
progress in this ﬁeld is incessant, while expertise and knowl-
edge are constantly accumulating. Therefore, it is not always
appropriate to consider the present guidelines all-inclusive and
deﬁnitive. Consequently, when testing and evaluating each
product, it is necessary to adopt, on a case-by-case basis, a
ﬂexible approach according to a rationale that reﬂects the sci-
entiﬁc and technological advances at that point in time.
2. The main purpose of evaluating the quality and safety of the
desired cell products before conducting investigational clinical
trials (e.g., at the time of “clinical-trial consultation”) is to
determinewhether there are any quality and/or safety problems
that would obviously hinder initiation of human clinical trials of
the iPS(-like) cell-based products in question, whether certain
quality attributes (QA) of the product are understood sufﬁ-
ciently to establish a relationship between the clinical ﬁndings
and the QA, and whether consistency of the QA can be ensured
within a deﬁnite range. Simultaneously, it is important to
eliminate any known risk factors associated with the product
quality and safety as much as possible, using up-to-date science
and technology, and to describe the scientiﬁc appropriateness of
the results of such an action. The remaining presumed risk
factors should be weighed against the risks associated with not
performing the trials on patients who suffer from diseases that
are serious and life-threatening or that involve marked func-
tional impairment or a marked decrease in quality of life (QOL)
resulting from the loss of a certain degree of physical function or
form, or for which existing therapies have limitations and do not
result in a cure. Furthermore, it is also important to entrust the
patient with the right to make a decision, after receiving all of
the available information. When applying for approval of
investigational clinical trials, applicants can submit a provisional
nonclinical data package, which is prepared rationally by taking
into account product aspects and patient aspects including a
balance between the risk of the product vs. the risk facing the
patient with/without treatment in question, for the decision to
initiate investigational clinical trials, on the premise that the
data package submitted at the time of marketing application/
registration to ensure quality and safety will be enriched in line
with the guidelines as the clinical trial progress.
Finally, applicants are encouraged to discuss with the Pharma-
ceuticals and Medical Devices Agency (PMDA) the type andamount of data that may be needed to initiate a particular
clinical trial. Because of differences in product origin, target
disease, target patients, application sites, application methods,
and processing methods, there may be numerous variations
among individual data packages; these differences cannot be
deﬁnitively clariﬁed in the present guidelines.
3. The items, test methods, criteria, and any other technical re-
quirements described in the present guidelines are intended to
be considered, selected, applied, and evaluated to serve each
intended purpose; they do not necessarily require the most
stringent level of interpretation and practice. Applicants are
encouraged to explain and provide justiﬁcation for any consid-
erations regarding the background, selection, application, and
the content as well as the extent of evaluation that are appro-
priate for their own purpose and are scientiﬁcally valid.3. Chapter I. General principles
3.1. Objective
The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of autologous human induced
pluripotent stem (iPS) cells or autologous iPS-like cells (excluding
allogeneic human iPS cells and allogeneic iPS-like cells). These
products are hereafter referred to as autologous human iPS(-like)
cell-based products or simply as the “desired cell products.”
3.2. Deﬁnitions
The deﬁnitions of the technical terms used in these guidelines
are as follows:
1. “Human induced pluripotent stem cells (iPS cells)”: Cells that
are generated from somatic cells through artiﬁcial reprogram-
ming by introducing genes or proteins, or via chemical or drug
treatment, or cells that are obtained from such cells through cell
division, and which possess the ability to differentiate into the
endoderm, mesoderm, and ectoderm, and furthermore to
maintain the ability to self-renew or a similar ability.
2. “Human induced pluripotent stem-like cells (iPS-like cells)”:
Cells that are generated from somatic cells through artiﬁcial
dedifferentiation by introducing genes or proteins, or via
chemical or drug treatment, or cells that are obtained from such
cells through cell division, and which at least possess the ability
to differentiate into some type of endoderm, mesoderm, or
ectoderm, and furthermore maintain the ability to self-renew or
a similar ability.
3. “Processing of cells and tissues”: Any processing of a cell type or
tissue, such as propagation and/or differentiation, production of
a cell line, activation of a cell by pharmaceutical or chemical
treatment, alteration of a biological characteristic, combination
with a noncellular component, or manipulation using genetic
engineering, with the aim of preparing desired cell products to
treat a patient or to repair or regenerate tissues.
Isolation of a tissue, homogenization of a tissue, separation of
cells, isolation of a speciﬁc cell, treatment with antibiotics,
washing, sterilization by g-irradiation or other methods,
freezing, thawing, and other such procedures that are regarded
as minimal manipulations, are not considered “processing.”
4. “Manufacture”: Actions undertaken before the ﬁnal product (an
autologous human iPS(-like) cell-based product) is released to
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tissues, minimal manipulations such as isolation of a tissue,
homogenization of a tissue, separation of cells, isolation of a
speciﬁc cell, treatment with antibiotics, washing, sterilization by
g-irradiation or other methods, freezing, thawing, and other
procedures that do not change the original properties of the
cells or tissues.
5. “Phenotype”: A morphological or physiological characteristic
that is produced by a certain gene under constant environ-
mental conditions.
6. “Donor”: A person who donates his/her own somatic cells,
which serve as a raw material for an autologous human iPS(-
like) cell-based product. For such a product, a patient is deﬁ-
nitely a donor. (Note: A patient is identiﬁed as a donor for actual
treatment. It is also presumed that cells/tissues obtained from a
donor other than a patient are used for the purpose of test
production during R&D stages.)
7. “Transgenic construct”: A construct that contains a vector for
introducing a target gene (a speciﬁc gene encoding a desired
protein or RNA) into a target cell, the target gene itself, and the
coding sequences of the elements essential for the expression of
the target gene.
8. “Protein transductant”: A construct that contains a target pro-
tein and elements such as reagents necessary for introducing
the target protein into a target cell.4. Chapter II. Manufacturing methods
Describe all the important and relevant information con-
cerning the manufacturing method, taking into account the items
listed below. This information will contribute to ensuring the
quality, safety, and efﬁcacy of the ﬁnal product, and is important
for guaranteeing quality consistency from the manufacturing
perspective. It should be noted that assurance of quality and
safety and their consistency is achieved via mutual comple-
mentary measures throughout the manufacturing method as a
whole, and it is very important that the measures be rational and
serve the intended purpose. It is acceptable to omit a portion of
the items listed below, if the appropriate scientiﬁc basis for
ensuring the quality, safety, and constancy of the ﬁnal products
can be provided by means of suitably chosen quality tests or
controls of the ﬁnal product or intermediates, or control of the
manufacturing process.4.1. Raw materials and materials used in manufacturing
4.1.1. Human somatic cells that serve as raw materials
(1) Features of biological structure and function, and selection
criteria
Provide and explain the reasons for selecting the somatic cells used
as raw materials based on the characteristics of their biological
structure and function, such as morphological characteristics,
growth characteristics, biochemical indicators, immunological in-
dicators, speciﬁc substances produced, and other suitably chosen
and appropriate genotype or phenotype indicators (or markers). It
is acceptable to perform test production and tests using test spec-
imens obtained from a donor other than a patient at the R&D
stages, before beginning the clinical trials.
This should lead to the identiﬁcation of the critical cell charac-
teristics that are to be employed when preparing patient-derived
somatic cells as rawmaterials. It is recognized that such a study canonly be performed with certain limitations because there are
quantitative limits on samples as well as technological limitations.
(2) Donor considerations
To ensure the safety of patients, manufacturing personnel, and
healthcare workers, establish test parameters for any infections
that may be transmitted via the collected somatic cells, and provide
justiﬁcation for the parameters. Special consideration should be
given to hepatitis B virus (HBV), hepatitis C virus (HCV), human
immunodeﬁciency virus (HIV), and human T-lymphotropic virus
(HTLV).
Establish eligibility criteria that take into account the genetic
characteristics, the medical history, and the health condition of the
patient and explain the suitability of the donors. If donor genomic
or gene analysis is undertaken, it shall be conducted in accordance
with the “Ethical Guidelines for Analytical Research on Human
Genome and Gene” published jointly on February 8, 2013, and
revised on Novembr 25, 2014, by the Japanese Ministry of Educa-
tion, Culture, Sports, Science and Technology; the Ministry of
Health, Labour and Welfare; and the Ministry of Economy, Trade
and Industry.
(3) Donor records
Complete donor records shall be retained so that any informa-
tion required to ensure the safety of the somatic cells used as raw
materials can be veriﬁed. Concrete measures shall be described. For
patients and donors of test samples, it is sufﬁcient to prepare and
retain speciﬁc information corresponding to the intended use of
individual cells.
(4) Collection, storage, and transport of cells and tissues
(i) Eligibility of personnel and medical institutions col-
lecting the samples
Describe the technical requirements for the
personnel andmedical institutions that collect the cells
and tissues.
(ii) Suitability of the sampling site and sampling method
Describe the rationale for selecting the cell and tissue
sampling sites as well as the sampling method and
clearly state why the selected sites are both scientiﬁ-
cally and ethically appropriate. For the cell and tissue
sampling methods, indicate the suitability of the
equipment and drugs used and the measures adopted
to prevent microbial contamination, erroneous sam-
pling (mix-up), and cross-contamination.
(iii) Informed consent of donors
Describe the details of the informed consent ob-
tained from the donor of the cells and/or tissues.
(iv) Protection of donor privacy
Indicate the measures adopted to ensure protection
of donor privacy.
(v) Tests to ensure donor safety
If tests, such as those to conﬁrm the state of the
sampling site, must be performed to ensure donor
safety at the time of cell or tissue sampling, describe
the details of the tests as well as any interventions
undertaken after test results indicate a problem.
(vi) A Storage method and measures to prevent erroneous
sampling (mix-up)
If the somatic cells collected must be stored for a
deﬁned period of time, set the storage conditions and
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idity). Describe in detail the measures and procedures
to be followed to prevent erroneous sampling (mix-
up).
(vii) Transportation methods
If cells and/or tissues or iPS(-like) cells that were
collected must be transported, deﬁne the containers to
be used for transport and the transportation pro-
cedures (including temperature control), and provide
the justiﬁcation.
(viii) Preparation of records and storage procedures
Written records for items (i) through (vii) above shall
be prepared, and proper record storage procedures
shall be described in detail.4.1.2. Raw materials other than target cells and tissues as well as
materials used in the manufacturing
Describe any raw materials other than the target cells and tis-
sues as well as other materials used in the manufacturing process,
indicate their appropriateness for their intended use, and if
necessary, establish their speciﬁcations (a set of acceptance criteria
and analytical procedures). Proper quality control of these mate-
rials should be implemented.
When so-called Biological Products or Speciﬁc Biological Prod-
ucts (refer to Articles 2.9 and 2.10 of the Pharmaceutical Affairs
Law) are used as rawmaterials, the amounts used should be kept to
the minimum amount required and should strictly conform to the
relevant laws and regulations, such as the “Standards for Biological
Raw Materials” (Notiﬁcation Number 210, Japanese Ministry of
Health, Labour and Welfare, 2003; a partially revised version was
issued on September 26, 2014). It is particularly important to
adequately evaluate information related to the inactivation and
elimination of viruses and to specify measures for encouraging
retrospective survey and other studies.
The technical requirements described in this paragraph should
be taken into consideration when the process of reprogramming or
dedifferentiation from the raw materials into iPS(-like) cells or of
directed differentiation from iPS(-like) cells into the ﬁnal products
in question, includes any relevant elements/concerns.
(1) Cell culture
(i) Indicate the appropriateness of all components of any
media including such as additives (e.g., serum, growth
factors, and antibiotics), and reagents used in the
treatment of cells, and set speciﬁcations if necessary.
Consider the route of clinical application (and other
parameters) of the ﬁnal product when setting speciﬁ-
cations concerning the appropriateness of each
component.
(ii) Consider the following points with respect to media
components:
(a) The ingredients and water used in media should be
of high quality and high biological purity; quality
should be controlled using standards equivalent to
those for pharmaceuticals and pharmaceutical
ingredients.
(b) Provide information on not only the main in-
gredients used in media, but all components as
well as the rationale for their selection, and if
necessary, the quality control and other pro-
cedures. However, widely known and commer-
cially available media products such as DMEM,
MCDB, HAM, and RPMI are regarded as a single
raw-material set.(c) Conduct sterility and performance tests on media
that contain all components to determine their
suitability as target media. Set speciﬁcations for
any other relevant parameters thought to be
controlled in the manufacturing process and
perform proper quality control.(iii) Heterologous serum or components derived from
heterologous or homologous serum shall not be used
unless they are essential for processes such as cell
activation or cell growth. In particular, for products that
may be used repeatedly, investigate, to the extent
possible, ways to avoid using these serum components.
If the use of serum or other such materials is un-
avoidable, consider the following points, and investi-
gate ways to prevent the contamination and
transmission of bacteria, fungi, viruses, and prions from
the serum and other related materials as well as
treatment methods for their elimination, to the extent
possible, from the ﬁnal product.
(a) Clarify the origin of the serum or other
components.
(b) Make strenuous efforts to minimize the risk of
prion infection, for example, by strictly avoiding
the use of serum from areas or regions with known
outbreaks of bovine spongiform encephalopathy
(BSE).
(c) Use these batches of serum only after conﬁrming
that they are not contaminated with viruses or
other pathogens by conducting appropriate tests to
prove the absence of speciﬁc viruses and myco-
plasma that originate in animal species.
(d) Conduct appropriate inactivation and elimination
procedures for bacteria, fungi, and viruses to an
extent that does not impact the activation and
growth of the cells. For example, to avoid the risks
associated with latent viral contamination, use
combinations of heat treatment, ﬁltration, g-irra-
diation, and/or ultraviolet light treatment, if
necessary.
(e) Preserve and store a portion of the serum used to
enable monitoring of cultured cells for viral in-
fections and onset of viral diseases among the pa-
tients and measure antigen production in response
to a component of the heterologous serum used.(iv) When using feeder cells, conduct quality evaluation
while referring to “Derivation and Characterization of
Cell Substrates Used for Production of Biotechnolog-
ical/Biological Products” (Pharmaceutical Notiﬁcation
Number 873, July issued 14, 2000, Evaluation and
Licensing Division, Pharmaceutical snd Food Safety
Bureau, Japanese Ministry of Health, Labour and Wel-
fare), “Guidelines on Public Health Infection Issues
Accompanying Xenotransplantations” (Notiﬁcation
0709001, issued July 9, 2002, Research and Develop-
ment Division, Health Policy Bureau, Japanese Ministry
of Health, Labour and Welfare), and “Guidelines on
Epithelial Regenerative Therapy Using 3T3J2 Strain or
3T3NIH Strain Cells as Feeder Cells” based on “Guide-
lines on Public Health Infection Issues Accompanying
Xenotransplantations” (Notiﬁcation 0702001, issued
July 2, 2004, Research and Development Division,
Health Policy Bureau, Japanese Ministry of Health, La-
bour and Welfare) in order to prevent contamination
and transmission of bacteria, fungi, viruses, and prions
from the feeder cells; indicate the methods used for
T. Hayakawa et al. / Regenerative Therapy 2 (2015) 81e94 87inactivation of the cell division potential; and state
conditions such as cell density. However, for example, if
the feeder cells or equivalent cells are being used in the
manufacture of a cell or tissue product that has previ-
ously been used clinically and whose characteristics
and microbiological safety have already been assessed
and conﬁrmed, it is possible to omit the virus tests or
portions of other tests by demonstrating the appro-
priateness of using these cells.
(v) The use of antibiotics should be avoided as much as
possible. However, if antibiotics are deemed indis-
pensable at the initial stages of processing, attempt to
decrease their use at subsequent steps as much as
possible and clearly state the appropriateness of their
use, including the scientiﬁc rationale, estimated resid-
ual amounts in the ﬁnal product, and effects on the
patient. If it has been determined that an antibiotic can
be adequately eliminated from the ﬁnal product, its use
does not need to be restricted. However, if a patient has
a history of allergy to the antibiotic used, this thera-
peutic method should not be used. If the use of anti-
biotics cannot be avoided, administer them carefully
and ensure that informed consent is obtained from the
patient.
(vi) If growth factors are used, demonstrate appropriate
quality control methods using relevant parameters, for
example purity and potency, for which established
acceptance criteria and assay methods are employed,
to guarantee the reproducibility of cell culture
characteristics.
(vii) For media components and other components used in
manipulation and those that may contaminate the ﬁnal
product, choose components with no harmful biolog-
ical effects.
(viii) When using cells derived from a different species
(heterologous cells) as feeder cells, ensure that there is
no risk of infection from the cells of heterologous
origin.(2) Combination of cells with noncellular components
(i) Quality and safety of noncellular raw materials
If the ﬁnal product consists of cells combined with
noncellular components, such as a matrix, medical ma-
terials, scaffolds, support membranes, ﬁbers, or beads,
describe in detail the quality and safety of the noncel-
lular components.
Provide any relevant information concerning the
noncellular raw materials, taking into consideration
their type and characteristics; the form and function in
the ﬁnal product; and evaluation of their quality, safety,
and efﬁcacy for the presumed clinical indication. When
using materials that are absorbed by the body, perform
the necessary tests for the safety of the degradation
products.
To determine which tests are required, refer to “Basic
Views on Biological Tests Necessary for Regulatory
Approval for Manufactured or Imported Medical De-
vices” (Notiﬁcation No. 0213001, issued February 13,
2003, Evaluation and Licensing Division, Pharmaceutical
and Food Safety Bureau, Japanese Ministry of Health,
Labour and Welfare), describe the test results, and pro-
vide justiﬁcation for the use of such raw materials.
Rational use of information from scientiﬁc literature is
also encouraged.(ii) Interactions with target cells
Demonstrate the validity of the tests used and provide
justiﬁcation for the results obtained for the following 3
items with respect to the interactions between noncel-
lular components and cells in the ﬁnal product and in
any intermediate products.
(a) The noncellular components do not have any dele-
terious effects on the function, growth capacity, ac-
tivity, or stability of the cells in the ﬁnal product
required for the presumed clinical indication or the
cells in any intermediate products.
(b) Evaluate to the extent possible any potential in-
teractions between cells and noncellular compo-
nents, taking into consideration, for example,
mutation, transformation, and/or dedifferentiation
of the cells in the ﬁnal or intermediate products.
(c) Demonstrate that there is no loss of the expected
properties of the noncellular components for the
presumed clinical indication due to any interactions
between the noncellular components and the cells
in the ﬁnal and intermediate products.(iii) Use of noncellular components to isolate the desired cell
products from the application site
When using noncellular components with the objec-
tive of segregating the desired cell products from the
application site, conﬁrm their usefulness and safety by
referring to points (a) through (d) below.
(a) Membrane permeability kinetics and pharmacolog-
ical effects of target physiologically active
substances derived from the cells in the ﬁnal
product.
(b) Diffusion of nutritional components and excretory
products.
(c) Effects of noncellular components on the area near
the application site.
(d) When a pharmacological effect of a target physio-
logically active substance derived from a desired cell
product is anticipated, and segregation of the
application site and the desired cell product and/or
undifferentiated cells is the objective, conﬁrm that
the cells will not leak after, for example, degradation
of the noncellular components.(3) Genetic modiﬁcation of cells
When genes are introduced into cells, provide details on
the following items:
(i) For the target gene (the speciﬁc gene encoding a desired
protein or RNA): information related to its structure,
origin, method by which it was obtained, cloning
methods; for the cell bank of the target gene: methods
of preparation of the cell bank, control, and renewal, and
other relevant techniques.
(ii) Nature of the transgene.
(iii) Structure, biological activity, and properties of the
desired proteins or RNA derived from the target gene.
(iv) All the raw materials, their properties, and procedures
(transgenic methods, and origin, properties, andmethod
for obtaining the vector used for introduction of
the transgene) required to produce the transgenic
construct.
(v) Structure and characteristics of the transgenic construct.
(vi) Control and preparation methods for cell and virus
banks that are used to prepare vectors and transgenic
constructs.
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Chapter 2 and other sections of the “Guidelines for Ensuring the
Quality and Safety of Gene Therapy Pharmaceuticals,” which is an
appendix of “Concerning Guidelines for Ensuring the Quality and
Safety of Gene Therapy Pharmaceuticals” (hereafter referred to as
“Gene Therapy Pharmaceutical Guidelines”), published as Notiﬁ-
cation No. 1062 by Pharmaceuyical Affairs Bureau, Japanese Min-
istry of Health and Welfare on November 15, 1995. In addition,
clearly state the appropriateness of the establishment of cell lines
in accordance with the appendix of the same notiﬁcation.
Be aware that, based on the law (Law No. 97, 2003) for ensuring
the biodiversity of living organisms by regulating the use (and
other aspects) of genetically modiﬁed organisms and related or-
ganisms, a separate application procedure for evaluation will be
required when living organisms, including certain cells, as well
“viruses” and “viroids,” are genetically modiﬁed. The following cells
are not regarded as living organisms: “human cells” or “cells that
have the ability to differentiate, or differentiated cells that are not
viable when alone, under natural conditions.”
Regardless of the above, if a gene introduced into cells is used as
a reagent in the manufacturing process but is neither chemically
nor functionally present in the ﬁnal product, it is acceptable to
simply describe how the quality and safety of the gene matches the
intended use, based on the most current knowledge.
(4) Introduction of proteins into cells
When proteins are introduced into cells, provide the de-
tails of the items listed below.
(i) Origin and quality attributes, including protein struc-
ture, biological activity, and physicochemical properties.
(ii) Information concerning the procurement,
manufacturing, quality control, and renewal methods
for the proteins.
(iii) Methods for introducing the proteins into the cells.
(iv) Quality attributes, including the structure, biological
activity, and physicochemical properties of the chem-
ical substances used to introduce the proteins into the
cells.
(v) When preparing a construct for introducing the protein
in question into cells, provide information on its prep-
aration, quality control, and renewal methods.
(vi) Preparation of cell banks and cell bank control methods
to produce the introduced proteins.Regardless of the above, if a protein that is introduced into cells
is used as a reagent in the manufacturing process but is neither
chemically nor functionally present in the ﬁnal product, it is
acceptable to simply describe how the quality and safety of the
protein corresponds to the intended use.
(5) Reprogramming or inducing dedifferentiation and/or differ-
entiation of cells using drugs or any chemicals
When inducing reprogramming or dedifferentiation, and/
or differentiation using drugs or any other chemicals, provide
the details on the following items.
(i) Orgin and quality attributes, including structure, bio-
logical activity (if any), and physicochemical properties
of the drugs or chemicals in question.
(ii) Information concerning the procurement,
manufacturing, quality control, and renewal methods
for the target drugs or chemicals.
(iii) Cell treatment methods using, for example, target drugs.(6) Cell reprogramming or dedifferentiation, and/or differentia-
tion using physical methodsDescribe the details of the methods used when inducing
cell reprogramming or dedifferentiation and/or differentia-
tion using physical methods in question.
(7) Cell reprogramming, dedifferentiation, and/or differentiation
using a combination of methods
Describe the details of the methods when using any com-
bination of genetic modiﬁcation, introduction of a protein,
drug/chemical treatment, or physical methods to induce cell
reprogramming, dedifferentiation, and/or differentiation.4.1.3. Establishment of autologous human iPS(-like) cell lines
Describe the methods used up until the establishment of
autologous human iPS(-like) cell lines from the somatic cells that
serve as the raw material, and indicate, as thoroughly as possible,
the appropriateness of the methods. These include the methods for
obtaining the human somatic cells, for separating and culturing of
somatic cells, for inducing reprogramming or dedifferentiation of
the somatic cells, for isolating and preparing cell lines of the
reprogrammed or dedifferentiated cells as well as the media, cul-
ture conditions, culture period, yield, and other parameters at each
step in the process until establishment of the autologous human
iPS(-like) cell line.
In order to maintain stability and consistency of the quality of
the human iPS(-like) cell lines, identify critical quality attributes of
the cells (for example, cell population purity, morphological fea-
tures, phenotype-speciﬁc markers, karyotype, cell growth proper-
ties, and pluripotency) and set acceptance criteria for them. In
addition, demonstrate the number of passages or of cell divisions
withinwhich cells can proliferatewhilemaintaining their quality in
terms of the criteria speciﬁed.
4.1.4. Storage and transport of human iPS(-like) cell lines
For human iPS(-like) cell lines, perform appropriate stability
tests based on the viability, potency, and other characteristics of the
cells, establish the storage method and validity period, and clarify
their suitability, considering storage duration, distribution, and the
storage form. In particular, when freezing and thawing, conﬁrm
whether freezing and thawing affect the stability or any other
characteristic of the cell line. Where necessary and possible,
conduct stability studies on the cell line whose storage period ex-
ceeds normal periods in order to conﬁrm, to the extent possible, the
limits of stability. However, this does not apply if the cells will be
used immediately after being established.
When transporting human iPS(-like) cells, the containers used
for transport and the transportation procedures (including tem-
perature control) shall be determined and their appropriateness
clearly indicated.
4.1.5. Preparation of records and storage procedures
Written records for items 4.1.2e4.1.4 above shall be prepared
and proper record storage procedures shall be clearly described.
4.2. Manufacturing process
When manufacturing autologous human iPS(-like) cell-based
products, describe in detail the manufacturing method and verify,
as thoroughly as possible, the appropriateness of the method using
the items listed below to maintain consistent product quality.
4.2.1. Lot control
Indicate whether a lot control procedure is applied for ﬁnal and
intermediate products. If any lot control is adopted, establish
standardized procedures for the makeup and control of the lot,
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method and acceptance criteria.
4.2.2. Manufacturing method
Provide an outline of the manufacturing method from the time
of receipt of the cells and tissues or somatic cells (that serve as the
rawmaterials) to the establishment of autologous human iPS(-like)
cells and cells that have progressed to the differentiation stage and
then to the ﬁnal product. Describe the technical details of the
process and the required process and product quality control.
(1) Tests upon receipt
Establish a battery of tests and acceptance criteria to assess
appropriateness of the cells and tissues or somatic cells that will
serve as the raw materials, taking into account the nature of the
cells and their intended use. These may include, for example, visual
tests, microscopic examination, recovery factors of target cells, cell
viability, characterization of cells and tissues, and microbiological
tests. At the stage of initiation of clinical trials, provide the actual
measured values obtained on test samples and propose a provi-
sional set of acceptance criteria based on these values.
(2) Inactivation and elimination of bacteria, fungi, viruses, and
other microorganisms
For cells and tissues or human somatic cells or autologous hu-
man iPS(-like) cells that serve as raw materials, inactivate and
eliminate bacteria, fungi, viruses, and other microorganisms if
necessary and whenever possible, to such an extent that the pro-
cedures do not have any effect on the cell viability, phenotype,
genetic traits, speciﬁc functions, quality or other characteristics of
the cells and tissues serving as rawmaterials. State the suitability of
the measures, procedures, and evaluation methods employed, if
any.
(3) Tissue homogenization, cell separation, isolation of speciﬁc
cells, and other techniques
Describe themethods for homogenization of a tissue, separation
of somatic cells, isolation of speciﬁc somatic cells, and methods for
washing of these cells and tissues (and other methods) in order to
generate the iPS(-like) cells, (the procedures that are performed at
the early stages of manufacture of the iPS(-like) cell-based products
from the collected cells and tissues). Upon isolating the speciﬁc
somatic cells, establish identiﬁcation methods for the cells.
(4) Establishment of autologous human iPS(-like) cell lines
Describe the methods used up until the establishment of iPS(-
like) cells from somatic cells that serve as the raw material, and
describe, as thoroughly as possible, the validity of the methods.
Identify critical quality attributes of the cells and set acceptance
criteria for them. Demonstrate the number of passages or cell di-
visions within which cells can proliferate while maintaining their
quality in terms of the criteria speciﬁed (refer to Chapter II-4eI-3).
(5) Establishment of an intermediate cell line derived from
autologous human iPS(-like) cells
It should be noted that in some cases, the establishment of a cell
line (intermediate cell line) as an intermediate product may be
important for the stable manufacture of a safe ﬁnal product and for
scientiﬁc validity of the procedure.When such ameasure is chosen,
explain its advantages and appropriateness. If a cell line thatexhibits a different phenotype is established in stages, describe the
methods (for example, methods for induction of differentiation,
isolation, culturing, and cell line establishment of the target cells as
well as the media, culture conditions, culture duration, the yield at
each stage) until establishment of each respective cell line and
explain their appropriateness to the extent possible.
To maintain the stability and consistency of the quality of the
intermediate cell lines, identify critical quality attributes of the cells
(for example, cell population purity, morphological features,
phenotype-speciﬁc markers, karyotype, cell growth properties, and
differentiation potency) and set acceptance criteria. Demonstrate
the number of passages or of cell divisions within which cells can
proliferate while maintaining their quality in terms of the criteria
speciﬁed. Although comprehensive cell characterization is always
desirable, it is recognized that quantitative limits on samples or
technological limits maymake it difﬁcult to perform the study fully.
If this is the case, it is acceptable to perform a limited study to the
extent possible.
If establishing and utilizing a cell bank from an intermediate cell
line in accordance with the above, refer to point (7).
(6) Preparation of cells that compose a principal component of
the ﬁnal product and serve as an active ingredient
Describe the methods, either directly from a human iPS(-like)
cell line or from an intermediate cell line derived from human
iPS(-like) cells, that are used to prepare the cells that serve as the
active ingredient in the ﬁnal product. Describe the induction of
differentiation, isolation, and culturing of the desired cells as well
as the media, culture conditions, culture duration, the yield of the
desired cells, and other characteristics at each step. Describe the
appropriateness of each method, to the extent possible.
(7) Establishment of cell banks
When a cell bank is established at any stage during the process
of manufacturing autologous human iPS(-like) cell-based products,
describe the details of the rationale for preparing the cell bank; the
methods used to prepare the cell bank; characterization of the cell
bank; and storage, maintenance, control, and renewal methods as
well as any other processes and tests performed and provide
justiﬁcation for each. Refer to “Derivation and Characterization of
Cell Substrates Used for Production of Biotechnological/Biological
Products” (Pharmaceutical Notiﬁcation No. 873, Evaluation and
Licensing Division, Pharmaceutical and Food Safety Bureau, Min-
istry of Health, Labour and Welfare of Japan, July 14, 2000) and
other relevant documents. It is acceptable to omit a portion of the
test items if the cells have been properly evaluated at an upstream
point in the process (for a valid reason) or if the cells are of autol-
ogous origin.
(8) Measures to prevent erroneous sampling (mix-up) and
cross-contamination during the manufacturing process
It is extremely important to prevent erroneous sampling and
cross-contamination during the manufacturing process when
manufacturing autologous human iPS(-like) cell-based products.
Therefore, clearly describe preventive measures in the control
process.
4.2.3. Characterization of cells that comprise a principal component
of a ﬁnal product and serve as an active ingredient
Analyze various attributes of the cells, such as cell population
purity, to control contaminationwith undifferentiated or nontarget
cells, cell viability, morphological characteristics, growth
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distinctive substances produced by cells, karyotype, differentiation
potency, and other appropriate genotypic and phenotypic markers
of the cells that makeup a principal component of the ﬁnal product.
Additionally, characterize the cells in relation to biological func-
tions, where necessary. Furthermore, to evaluate the appropriate-
ness of the culture duration and stability of the cells, use
appropriate markers of cell characteristics to prove the absence of
unintended changes in cells cultured beyond the proposed culture
period. It is acceptable to perform these studies preliminarily, using
test samples obtained from donors who are not patients in place of
the products that will be prepared for a clinical trial. These results
can be used to identify the critical cell characteristics that should be
used when applying the real product to the treatment of a patient.
Although comprehensive cell characterization is always desirable,
quantitative limits on samples or technological limitations may
prevent full characterization. In this case, it is acceptable to perform
a limited study to the extent possible. When cell processing, such as
growth within the body, is anticipated after clinical application,
clearly demonstrate the functions expected using the passage
number or number of cell divisions based on the speciﬁed criteria.4.2.4. The form and packaging of the ﬁnal product
The form and packaging of the ﬁnal product shall ensure the
quality of the ﬁnal product.4.2.5. Storage and transport of the ﬁnal product
If an intermediate or ﬁnal product must be stored and trans-
ported, the storage procedure and duration, the containers used for
transport, and the transportation procedure (including tempera-
ture control) shall be stated and their appropriateness clearly
indicated (refer to Chapter III).4.2.6. Consistency of the manufacturing procedure
To assess the consistency of the manufacturing process using
each product (each lot) obtained from different production runs,
determine whether they differ signiﬁcantly with respect to the
number of cells, cell viability, and cell characteristics (such as
relevant markers of a phenotype and/or genotype, functional
characteristics, and the percentage of desired cells), considering the
application methods and intended use of the product. It is
acceptable to use test samples obtained from donors who are not
patients in place of the real products that will be prepared for a
clinical trial. Evaluation using intermediate products may provide
an accurate explanation of the suitability of the cells and tissues for
use as raw materials and the validity of the manufacturing process
until the point of production of the intermediate products as well as
may serve as an appropriate guidepost leading up to the ﬁnal
product. Therefore, it may be reasonable to adopt such an approach,
where necessary and appropriate.
When the duration of the cryopreservation or cell cultivation
portion of the manufacturing process is lengthy, perform sterili-
zation tests and other relevant procedures at consistent intervals to
conﬁrm that sterility has been preserved.4.2.7. Changes in the manufacturing process
If the manufacturing process is altered at some point during
development, and if test results that are obtained using products
manufactured prior to the change are to be used in the application
for clinical-trial or regulatory approval, demonstrate the compa-
rability of the products manufactured before and after the
alteration.4.3. Quality control of the ﬁnal product
4.3.1. Introduction
The overall quality control strategy for autologous human iPS(-
like) cell-based products includes speciﬁcations (a set of accep-
tance criteria and analytical procedures) for ﬁnal products, quality
control of raw materials for each therapeutic application to each
patient, veriﬁcation of the appropriateness of the manufacturing
process, and maintenance of its consistency as well as proper
quality control of intermediate products, if any. One of the most
critical issues in case of iPS(-like) cell-based products is a measure
to ensure the absence of contamination of the cells by undiffer-
entiated cells other than the desired cells. Veriﬁcation of the
absence of contamination by nontarget undifferentiated cells is
desirable, as much as possible, at the intermediate-product stage.
Speciﬁcations will differ among ﬁnal products, depending on
the type and properties of the desired cells and tissues,
manufacturing methods, intended clinical use, the method of
clinical application of each product, stability, and available test
methods. These differences shall be taken into consideration when
setting acceptance criteria and analytical procedures. In addition,
speciﬁcations shall be set and justiﬁed from the standpoint of
achieving the purpose of quality control as a whole, by taking into
consideration the mutually complementary relationships among 1)
veriﬁcation of the suitability of the manufacturing process, 2) the
method for maintaining consistency, and 3) quality control of the
raw materials and intermediate products. The purpose of the
assessment for initiating clinical trials is to conﬁrm that the product
in question is unlikely to pose signiﬁcant quality/safety problems
for use in investigational clinical trials. Therefore, it is possible to
set provisional speciﬁcations, with allowance for some variation,
based on values measured using a few test specimens, as long as
one can be certain of the relationships between the results of
clinical tests and such quality attributes after clinical trials. How-
ever, testing for sterility and the absence of mycoplasma is essen-
tial. It should be noted that the quality control strategy, including
speciﬁcations, shall be enriched and developed in tandemwith the
progress of clinical trials.4.3.2. Quality control of the ﬁnal product
Refer to the general quality control parameters and tests
described below, set appropriate speciﬁcations for the ﬁnal prod-
uct, and provide the rationale for the speciﬁcations set.
Set appropriate acceptance criteria and test procedures for in-
dividual products that do not comprise a lot as well as for individual
products that do comprise a lot because each lot is typically a unit
subjected to quality control.
(1) Cell number and cell viability
The number and viability of cells that are active ingredients in
the ﬁnal product, or in an appropriate intermediate product, if
required, should be determined. At the beginning of the clinical
trial, it is acceptable to set provisional acceptance criteria based on
actual measured values obtained for a small number of test
samples.
(2) Tests of identity
Conﬁrm that the cells are the intended target cells using
markers for critical cell characteristic(s) selected from the
morphological characteristics, biochemical markers, immunolog-
ical markers, characteristic products, and other appropriate geno-
types or phenotypes of the intended target cells and tissues.
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To test the purity of the cell population in a ﬁnal product, set the
test parameters, test methods, and acceptance criteria for evalu-
ating and controlling nontarget cells, such as undifferentiated cells,
cells exhibiting abnormal growth, transformed cells as well as the
presence of any other contaminating cells, considering the origin of
the target cells and tissues, the culture conditions and other pa-
rameters of the manufacturing process, such as quality control of
intermediate products. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria based onmeasured
values obtained for a small number of test samples.
(4) Tests for cell-derived undesirable physiologically active
substances
Specify appropriate tests for determining the permissible dose
limits of any potential undesirable physiologically active substances
that are derived from the target cells, if the presence of such sub-
stances in the product is presumed to clearly impact the safety of
the patients. At the beginning of the clinical trial, it is acceptable to
set provisional acceptance criteria based on measured values ob-
tained for a small number of test samples.
(5) Tests for process-related impurities
For substances that may be present in the ﬁnal product as, for
instance, contaminants, residues, newly generated products or
degradation products; that potentially originating from raw mate-
rials, noncellular components, media ingredients (including feeder
cells), chemical reagents, or any other process-related materials;
and that may have deleterious effect on the quality and safety (for
example, albumin derived from fetal calf serum and antibiotics), it
is necessary to 1) prove that the substance is not present in the ﬁnal
product using the results of process evaluation for the elimination
of the substance or the results of in-process control of the sub-
stance or 2) establish appropriate tests to control the amount of the
substance in the ﬁnal product within permissible levels. When
selecting substances to be tested and setting their acceptance
criteria, their suitability should be explained and justiﬁed.
At the beginning of the clinical trial, it is acceptable to set pro-
visional acceptance criteria based on measured values obtained for
a small number of test samples.
(6) Sterility tests and tests for the absence of mycoplasma
The sterility of the ﬁnal product should be adequately assessed
to ensure sterility throughout the entire manufacturing process,
using test samples. The sterility (negative results of tests for com-
mon bacteria and fungi) of the ﬁnal product should be demon-
strated in tests before use in a patient. Appropriate tests conﬁrming
the absence of mycoplasma should also be carried out. A validated
nucleic-acid ampliﬁcation test can be used. If the results of the
sterility and other tests of the ﬁnal product can be obtained only
after administration to the patient, the proper measures for dealing
with the potential lack of sterility should be established before-
hand. In such cases, the intermediate products must be demon-
strated to be sterile, and sterility should be strictly maintained in all
processes leading up to the ﬁnal product. If a product from the same
facility and same process has already been used in patients, its
sterility must be conﬁrmed by testing it in all patients. If complete
closure (hermetic seal) of an individual lot of the product has been
ensured, tests using only representative samples are sufﬁcient.
When tests must be conducted for each clinical application, and if
the results of sterility and other tests can be obtained only afteradministration to the patient, the decision on whether the clinical
application should proceed will be determined based on the most
recent data. However, even in this case, sterility tests and other
tests shall be performed on the ﬁnal product.
It is desirable that every effort be made to avoid the use of an-
tibiotics in cell culture systems; however, if they are used, adopt
measures to ensure that the antibiotics do not inﬂuence the sterility
tests.
(7) Endotoxin test
Perform an endotoxin test, considering the impact of a potential
contaminant in the samples. The acceptance criteria do not
necessarily depend on the actual measured values. It is recom-
mended to set acceptance criteria considering the safety ranges
given in the Japanese Pharmacopoeia and/or any other relevant
compendia based on a single dose of the ﬁnal product. Endotoxin
testing can be established as an in-process control test; however, in
such cases, establish criteria, including validation results, and
provide the justiﬁcation.
(8) Virus tests
If the absence of HBV, HCV, HIV, and HTLV cannot be proven at
the patient level, and if these viruses may proliferate in the cells,
conduct virus titer tests and conﬁrm that administration of the
iPS(-like) cell-based products will not lead to any adverse effects on
the patient. This does not apply if tests proving the absence of vi-
ruses are performed on intermediate products or at the cell bank. If
components of biological origin are used in the manufacturing
process, it may be necessary to conduct tests on the ﬁnal product
for viruses originating from those components. However, when-
ever possible, it is preferable to verify the absence of contamination
by testing or via process evaluation at the upstream stage, including
tests on the original components.
(9) Speciﬁc biological tests
In some instances, it will be necessary to consider speciﬁc
(quantitative or qualitative) biological testing that takes into
consideration the cell type, intended clinical use, or distinctive
characteristics of the cells. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria based onmeasured
values obtained for a small number of test samples.
(10) Potency assay
If the secretion of a speciﬁc physiologically active substance
from the cells or tissues is responsible for the efﬁcacy or the
essential effect of an autologous human iPS(-like) cell-based
product during its intended clinical use, establish test parameters
and/or acceptance criteria related to this substance in order to
demonstrate the intended effect. Set acceptance criteria for potency
or quantitation for a gene expression product secreted from the
cells when a transgene was introduced. At the beginning of the
clinical trial, it is acceptable to set provisional acceptance criteria
based on measured values obtained for a small number of test
samples.
(11) Mechanical compatibility tests
For products that require a certain degree of dynamic strength,
set acceptance criteria to conﬁrm mechanical compatibility and
durability that take into account the site of application. At the
beginning of the clinical trial, it is acceptable to set provisional
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5. Chapter III. Stability of autologous human iPS(-like) cell-
based products
Taking into full consideration the storage and distribution pe-
riods and the storage form, perform suitable stability testing on
autologous human iPS(-like) cell-based products and/or critical
intermediate products based on cell viability, potency, and other
characteristics to establish storage methods and expiration date,
and provide justiﬁcation for their suitability. In particular, when
freezing and thawing are involved in the storage and use of the
products, conﬁrm that the freezing and thawing processes do not
affect the stability or acceptance criteria of the product. Where
necessary and possible, it is recommended to conduct stability
studies on products whose manufacturing or storage period ex-
ceeds the normal period, in order to conﬁrm, as much as possible,
the limits of stability. This does not apply if a product will be used
immediately after production.
If a human iPS(-like) cell-based product will be transported, the
relevant transportation vessels and transportation procedures
(such as thermal management) shall be set and their appropriate-
ness justiﬁed.
6. Chapter IV. Preclinical safety testing of autologous human
iPS(-like) cell-based products
Relevant animal tests and/or in vitro tests may be performed to
elucidate concerns about the safety of an autologous human iPS(-
like) cell-based product when it is scientiﬁcally reasonable and
technically possible. Safety concerns about noncellular constituents
and process-related impurities should be resolved, as much as
possible, using physicochemical analyses and not animal testing. In
addition, the presence of undifferentiated cells in the ﬁnal product
and their potential to cause ectopic tissue formation, tumorige-
nicity, or malignant transformation are a safety concern. Therefore,
it is necessary to reduce the risk of contaminationwith such cells as
much as possible via thorough analysis at the cell bank and/or at
the intermediate-product stage, or by developing and utilizing
methods that effectively separate, remove, and/or inactivate these
contaminating undifferentiated cells from the target cells during
the manufacturing process. Furthermore, the administration route
for the target cells may be selected to aid in the minimization of the
safety risks.
Animal testing of products of human origin does not always
yield meaningful results. Thus, there may be a scientiﬁc rationale
for preparing product models of animal origin and testing on
appropriate experimental animals if more useful information may
be obtained. In such a case, consider conducting tests on suitable
animal models for each target disease. (Note: For example, mon-
keys may be suitable for neurological diseases, while pigs and/or
dogs may be suitable for cardiovascular diseases.) However,
because the use of identical procedures in nonhuman animals will
not necessarily yield cell groups that possess characteristics
identical to those of cells that constitute an autologous human
iPS(-like) cell-based product, and because a product of animal cell
origin that was manufactured using identical processing, including
culture conditions, will not necessarily be comparable to a human
cell product, careful feasibility studies are required beforehand
when adopting, conducting, and evaluating such studies. When
conducting animal experiments using iPS(-like) cell-based prod-
ucts obtained from nonhuman animal species, explain the suit-
ability of the extrapolation. Depending on the case, consider test
systems that employ cells, and clearly explain the appropriatenessof the test system when conducting tests using this kind of
approach.
The examples below present points to consider when conﬁrm-
ing the preclinical safety of a product. These are merely examples
for illustration and are not meant to suggest that tests be conducted
without a rational basis. Conduct necessary and appropriate tests,
taking into account the characteristics of the product, intended
clinical use, and other parameters, and evaluate and discuss the
results in a comprehensive manner.
1. For cells expanded beyond the deﬁned limit for cultivation
(duration of culture, the population doubling level, or the pas-
sage number of the cells) for routine production, clearly
demonstrate that undesirable alterations other than the inten-
ded transformation and abnormal proliferation of nontarget
cells have not occurred.
2. It may be necessary to conduct quantitative assays of particular
physiologically active substances produced by the cells and
tissues and to discuss their effects when given to patients. In
some cases, signiﬁcant amounts of active substances, including
cytokines and growth factors, would be produced by the cells,
potentially resulting in undesirable effects on the patients.
3. Examine and discuss the potential effects and safety conse-
quences of the product on the healthy cells and tissues of a
patient.
4. Investigate and discuss the possibility and potential safety
consequences of the formation of ectopic tissue by cells in the
product and/or contaminating undifferentiated cells when the
product is given to the patient. Discuss in a comprehensive
manner, taking into account the type and characteristics of the
product, the route of administration, target diseases, appropri-
ateness of the test system, and other characteristics.
5. Investigate and discuss the possibility and safety of undesirable
immunological reactions to the product and/or expression
product of a transgene and the relevant safety concerns.
6. Using an appropriate animal model or other system, investigate
and discuss the possibility of tumor formation including benign
tumors and/or malignant transformation of cells in the ﬁnal
product or an intermediate product. These studies should be
performed suitably by taking into account the type and char-
acteristics of the product, number of cells, route of administra-
tion, mode of application (e.g., cell sheet or cell suspension), cell
engraftment site, target diseases, appropriateness of the tests
systems, and other characteristics. If there is a possibility of
tumorigenicity or malignant transformation, provide justiﬁca-
tion for the use of the product in question and its rationale,
considering the relationshipwith the anticipated efﬁcacy. (Note:
The most important aspect of a tumorigenicity test is to accu-
rately assess the tumorigenicity of a ﬁnal product that will be
used in patients. However, it is conceivable that tumorigenicity
will need to be evaluated using cells from an intermediate
product because the cells comprising the ﬁnal product cannot
be used for various reasons, such as impossibility to obtain a
sufﬁcient number of cells. Furthermore, in tumorigenicity tests
using animal models, various conditions, such as cell dispersion
and cell adhesion to scaffolding, cell density, and administration
site, are not always identical to those for the ﬁnal product.
Sensitivity may differ depending on the species, strain, and
immunological state of the animal. The tumorigenicity of the
ﬁnal product should be evaluated with comprehensive consid-
eration of these circumstances. The risks to the patient arising
from tumorigenicity of the ﬁnal product should be rationally
evaluated based on the balance between any risks and the
beneﬁts to the patient as a result of treating the disease.)
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manufacturing process, and if it may function or remain as a
residue in the ﬁnal product, conduct tests in accordance with
the “Gene Therapy Pharmaceutical Guidelines.” In particular, if
viral vectors are used, determine quantitatively the potential
presence of any replication-competent viruses and provide
justiﬁcation for the test employed. Describe the safety of the
transgene and its products based on their characteristics. For
cells, discuss the possibility of changes in cell growth or the risk
of tumor formation, including benign tumors and malignant
transformation. Whenever a vector, which may get inserted into
a chromosome, is used, consider the necessity of evaluating
possible occurrence of abnormal proliferative characteristics
and/or tumorigenicity due to an insertion mutation in the cells,
and the necessity of implementing long-term follow-up for
clinical applications.
8. Consider conducting rationally designed general toxicological
tests, if the product, including an animal-derived model of
product, is easy to obtain, and if doing so will generate useful
information regarding its clinical application.
When conducting general toxicological tests, refer to the
“Guidelines for Toxicology Studies on Pharmaceuticals,” which
is an appendix to the document entitled “Guidelines on Toxi-
cology Studies Required for Regulatory Approval for the
Manufacture or Import of Pharmaceuticals” (Drug Evaluation
Notiﬁcation 1:24, issued September 11, 1988, New Drug Divi-
sion/Evaluation and Licensing Division, Pharmaceutical Affairs
Bureau, Japanese Ministry of Health and Welfare).
7. Chapter V. Studies supporting the potency or efﬁcacy of
autologous human iPS(-like) cell-based products
1. A well-designed study using experimental animals and/or cells
should be performed in order to demonstrate the functional
expression, sustainability of an effect, and/or anticipated clinical
efﬁcacy (proof of concept) of an autologous human iPS(-like)
cell-based product to the scientiﬁcally reasonable and techni-
cally possible extent.
2. For transgenic cells, demonstrate the expression efﬁciency,
sustainability of expression, and biological activity of desired
products derived from the (trans)gene. Discuss the rationale of
the transgene expression products as active ingredients for-
anticipated clinical efﬁcacy (proof of concept) of the autologous
human iPS(-like) cell-based product in question.
3. Where appropriate models of products derived from processing
of animal iPS(-like) cells and/or animal models of a disease are
available, use them to study the potential therapeutic efﬁcacy of
the product.
4. At the beginning of the clinical trial, detailed experimental
studies will not necessarily be required if the potency or efﬁcacy
of the therapy employing the product in question is expected to
be markedly superior to other therapeutic methods, and if this
can be justiﬁed by means of scientiﬁc literature and/or other
available information.8. Chapter VI. Pharmacokinetics of autologous human iPS(-
like) cell-based products
1. Pharmacokinetic studies of the internal behavior of cells/tissues
that constitute the ﬁnal products or expression products of
transgenes (these studies may include assessment of the ab-
sorption and distribution in experimental animals), should beperformed to the technically possible and scientiﬁcally reason-
able extent. Therefore, these studies are expected to estimate the
survival of cells/tissues administered to patients and the duration
of their effect and to determine whether the intended efﬁcacy is
successfully achieved. (Note: Testing methods may include his-
tological studies, human Alu sequences ampliﬁcation by poly-
merase chain reaction (Alu-PCR), magnetic resonance imaging
(MRI), positron emission tomography (PET), single photon emis-
sion computed tomography (SPECT) and bioimaging).
2. Clarify, using animal studies, the rationale for the administration
method for the autologous human iPS(-like) cell-based prod-
ucts. In particular, extrapolate from animal experiments, the
systemic distribution of cells after systemic administration and
discuss the distribution from the point of view of clinical use-
fulness. (Note: Although it is unclear exactly where the cells
adhere with each administration route, it is assumed that local
administration is preferable to systemic administration. How-
ever, if the beneﬁts to patients can be explained in a rational
manner, it is acceptable to use systemic administration. In any
case, an administration method that minimizes distribution of
an iPS(-like) cell-based product to organs other than the target
organ is preferred. Even if the cells localize to a site other than
the intended transplantation site, the administration method
is acceptable if patients experience no adverse effects.
Arrhythmia caused by osteogenesis of some types of cells that
ectopically locate to the heart is an example of an adverse
effect that can result from ectopic differentiation.)
3. When the cells or tissues are directly applied or alternatively
targeted to a speciﬁed site (e.g., tissue) where they can be ex-
pected to perform their actions, clarify the localization, and
discuss the effect of the localization on the efﬁcacy and safety of
the product.9. Chapter VII. Preliminary analysis of clinical trials
Themainpurposeof the present guidelines is to address points to
consider for evaluating the quality and safety of autologous human
iPS(-like) cell-based products at the time of application for mar-
keting authorization and at the beginning of investigational clinical
trials. In the latter case, it is necessary to determine whether any
quality or safety problems exist that might pose an obstacle to
initiation of human clinical trials, taking into consideration the
product's clinical usefulness. Thus, quality and nonclinical safety
evaluation for the decision to initiate the investigational clinical
trials of the product in question should be conductedwith reference
to the points outlined below. Any known risk factors associatedwith
the product's quality and safety should be eliminated, as much as
possible, using up-to-date science and technology, and the scientiﬁc
appropriateness should be clearly described. Any remaining risks
should beweighed against the risks associatedwith not performing
the trials on patients that suffer from diseases that are serious and
life-threatening, that involve marked functional impairment, or a
marked decrease of quality of life resulting from the loss of a certain
degree of a physical function or form, and for which existing ther-
apies have limitations and do not result in a cure. Furthermore, it is
also important to entrust the patient with the right to make a de-
cision after receiving all of the available information, including all
information on identiﬁed/presumed risks and anticipated beneﬁts.
(1) Target disease.
(2) Target subjects and patients who should be excluded as
participants.
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including the application of autologous human iPS(-like)
cell-based products and drugs used concomitantly. (Note: If
it is anticipated that drugs will be coadministered in order to
maintain, enhance, and/or induce the function of the
administered or transplanted cells, verify the intended ac-
tivity of the drugs either in vitro or in vivo.)
(4) Appropriateness of conducting the clinical trials in light of
existing therapeutic methods.
(5) Plan for explaining the clinical trial to the patients, including
the currently known risks and beneﬁts of the product.
Clinical trials should have an appropriate study design and
clearly speciﬁed endpoints. They should be designed in light of the
desired cells/tissues, target disease, and method of application.
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